Although an estimated 6-10% of physicians have ordered genetic tests to personalize prescribing or treatment for patients, the technology is not as widely adopted as many industry experts predicted it would be. Kristine Ashcraft, Genelex’s Director of Sales and Marketing, notes, “one of the key barriers to widespread adoption of personalized prescribing is the interpretation gap—the gap that exists between the information provided and a clinician’s ability to use it.” As a leader in the field since 2000, Genelex has encouraged input from the patients and healthcare providers we serve so we can continue to improve the tools and reports we provide so the positive healthcare impact of this technology can be fully realized. These are some improvements recently implemented, based on client feedback that we believe will further close the interpretation gap.
No Easy Way for Patient to Share Results with Other Providers – The graphic below shows cards that are now provided for patients. The in
formation on the cards allows any healthcare provider secure web access to GeneMedRx where they can reduce drug and gene interaction risk when making medication decisions.
formation on the cards allows any healthcare provider secure web access to GeneMedRx where they can reduce drug and gene interaction risk when making medication decisions. Specific Drug-Gene Interaction Requires GeneMedRx Login – We now provide drug-gene tables for all phenotypes. A graphic depicting a sample for CYP2D6 poor metabolizers (10% of patients) is to the right.
Reports Too Long – We have shortened our reports to one page for the three main cytochromes – 2D6, 2C9, and 2C19 as well as VKOR. A sample can be viewed at www.healthanddna.com/CombinedDST.pdf
If you are one of our referring physicians or previously tested patients and would like drug-gene tables or updated reports and patient cards, call 800 TEST-DNA or email info@genelex.com.
No comments:
Post a Comment